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Estrogen receptors (ERs) have long been implicated in the etiology of multiple sclerosis, but no
clear molecular mechanisms have linked ERs to the disease’s pathology. Now Saijo et al. (2011)
provide evidence that ERb activates a transrepression pathway that suppresses inflammation
and inhibits progression of pathology in a mouse model of multiple sclerosis.Multiple sclerosis (MS) is a debilitating
disease of the central nervous system
(CNS). It is characterized by the progres-
sive loss of the myelin sheath that wraps
axons and allows efficient communication
between neurons. The most prevalent
form of the disease is relapsing-remitting
MS. Considered an autoimmune disease,
relapsing-remitting MS consists of alter-
native periods of inflammation, in which
demyelination occurs, and remission. At
the cellular level, relapsing-remitting MS
is believed to be driven by three cell types:
activated proinflammatory microglia,
which are mononuclear phagocytic cells
resident in the CNS, and inflammatory T
helper 1 (Th1) and Th17 lymphocyte
subsets infiltrating the CNS.
The etiological factors contributing to
relapsing-remitting MS are not well under-
stood, but they likely involve both genetic
and environmental elements. In particular,
females suffering from relapsing-remitting
MS outnumber males by 3.21 to 1 in
Canada, a ratio that has continued to
increase in the past 50 years from 1.9:1
(Orton et al., 2006). Although the estrogen
receptors (ERs) have been implicated in
the etiology of MS, no clear molecular
mechanisms link them to relapsing-remit-
ting MS. Now, in this issue of Cell, Saijo
and colleagues may have filled in this
gap.Theyuncoveranendogenousmecha-
nism anchored by ERb, which suppresses
neuroinflammation and can inhibit pathol-
ogies similar to relapsing-remitting MS in
a mouse model of the disease.
Based on the observation that human
and mouse microglia express high levels
of the ERb transcript relative to that ofERa, Saijo et al. (2011) first look for
synthetic ligands specific for ERb, which
could modulate the inflammatory activity
of microglia cells in response to lipopoly-
saccharide (LPS) in vitro. LPS is an
agonist for the toll-like receptor 4 and is
often used experimentally to activate the
innate immune response in the brain
(Figure 1) (Rivest, 2009). The authors find
that, from an array of ERb ligands, only
the heterocyclic compounds Indazole-Br
and Indazole-Cl consistently inhibit
transcription of proinflammatory genes,
including inducible nitric oxide synthase
(iNOS), interleukin 1b (IL-1b), and
IL-23p19. Furthermore, reducing expres-
sion of ERb, but not ERa, completely
abrogates Indazole-Cl’s inhibition of
proinflammatory gene transcription, sug-
gesting that ERb mediates the repressive
effects of the Indazoles.
Saijo et al. next investigate the capacity
of Indazole-Cl to inhibit inflammation in
the CNS. In mice, experimental autoim-
mune encephalitis (EAE) recapitulates
several pathophysiological hallmarks of
relapsing-remitting MS, including progres-
sive paralysis, demyelination, and inflam-
mation sustained by microglia and acti-
vated T lymphocytes (e.g., Th17 cells)
(Yong and Rivest, 2009). Indeed, Saijo
and colleagues find that treating mice
with Indazole-Cl is strikingly effective
against EAE, both prophylactically and
therapeutically. Mice given Indazole-Cl
prior to the first signs of paralysis never
develop EAE, and the treated mice exhibit
reduced infiltration of Th17 cells in the
CNS,suggesting that Indazole-Cl success-
fully impairs the inflammatory responseCellnecessary for EAE. Evenmore remarkable,
however, is that treating mice with Inda-
zole-Cl after EAE begins not only inhibits
disease progression but also allows for
a recovery of the animals’ motor functions.
In both the prophylactic and thera-
peutic experiments, ERb is absolutely
necessary for Indazole-Cl to inhibit EAE;
when mice mutant for ERb (i.e., ERb/
mice) are treated with the drug, they
develop EAE similar to nontreated mice.
These data strongly suggest that activa-
tion of ERb by Indazole-Cl plays a pivotal
role in repressing CNS inflammation.
Next Saijo and colleagues look for
endogenous and naturally occurring
steroids that bind ERb and reduce inflam-
mation in the CNS. In particular, the ligand
5-androsten-3b, 17b-diol (ADIOL) can
inhibit expression of inflammatory genes
by ERb, and it can be synthesized from
its precursor dehydroepiandrosterone
(DHEA) within microglia (Jellinck et al.,
2007). As reported in previous studies
(Du et al., 2001), Saijo et al. (2011) also
find that DHEA represses inflammation
in EAE mice, although its effects are not
as extensive as ADIOL. Furthermore,
microglia express relatively high levels of
the enzyme 17b-hydroxysteroid dehydro-
genase (17b-HSD). 17b-HSD converts
DHEA into ADIOL, and inhibiting
17b-HSD renders DHEA ineffective at
repressing the transcription of the IL-6
gene in vitro. Together these data indicate
that microglia possess the machinery to
produce ADIOL, which can then bind to
ERb in an autocrine/paracrine manner.
Previous studies have described similar
anti-inflammatory and/or neuroprotective145, May 13, 2011 ª2011 Elsevier Inc. 495
Figure 1. A Possible Model for How Steroid Ligands Influence the Inflammatory Response in
Male versus Female Brains
Immune insults trigger proinflammatory signaling pathways in microglial cells through NF-kB (nuclear
factor kappa-light-chain-enhancer of activated B cells) and PKA (protein kinase A), leading to the tran-
scription of innate immune genes. Dehydroepiandrosterone (DHEA), which is present within the cerebral
environment, is the precursor of 5-androsten-3b, 17b-diol (ADIOL). ADIOL activates the estrogen receptor
beta (ERb), which then forms a complex with AP-1. The AP1-ERb complex recruits the corepressor
C-terminal binding protein 1 and 2 (CtBP), which shuts off the inflammatory genes. 17b-estradiol (17b-E2)
can antagonize the anti-inflammatory activities of ADIOL, leading to an increase in transcription of
proinflammatory genes. If levels of 17b-E2 are more abundant in female (right) versus male (left) brains, it
could shift the equilibrium between these endogenous ligands, resulting in a proinflammatory phenotype.
Such amodel would help explain why young females aremore susceptible thanmales tomultiple sclerosis
and possibly other autoimmune diseases.properties of ER activation and DHEA in
EAE (Du et al., 2001; Tiwari-Woodruff
and Voskuhl, 2009), but now Saijo and
colleagues provide a molecular mecha-
nism for these effects. Specifically, they
show that ERb can act by a ‘‘transrepres-
sive mechanism,’’ in which ERb blocks
transcription of proinflammatory genes
without binding directly to its target DNA
sequence, the estrogen-responsive
elements. Instead this repressive mecha-
nism requires AP-1—the transcription
factor that contains c-Fos—to bind to
promoters of proinflammatory genes
(Figure 1). Then the AP-1-ERb complex
recruits the corepressor C-terminal
binding protein 1 or 2 (CtBP), which
presumably disables the transcriptional
machinery (Stossi et al., 2009). Lastly, it
is worth noting that this ADIOL-ERb
mechanism promotes only the resolution
of inflammation because it interferes
with AP-1 only after proinflammatory496 Cell 145, May 13, 2011 ª2011 Elsevier Insignals (e.g., LPS, IL-1b) have activated
the transcription factor.
The study by Saijo and colleagues
raises a number of exciting questions
and hypotheses about how ERb modu-
lates gene transcription in the context of
inflammation. Although their data strongly
indicate that ADIOL-activated ERb re-
presses proinflammatory genes by a
transrepression mechanism, evidence in
the study also suggests that ERb may
directly regulate the initial activation of
a subset of proinflammatory genes. For
instance, decreasing the expression of
ERb by small inhibitory RNA in human mi-
croglia, in itself, diminishes LPS-induced
transcription of IL-1b but substantially
enhances IL-1b-induced transcription of
BAFF (B cell-activating factor) in astro-
cytes. Moreover, these effects of ERb
occur in theabsenceof IndazoleorADIOL.
Therefore, ERb appears capable of either
augmenting or diminishing the expressionc.of proinflammatory genes in response to
danger cues, but how it mediates this
differential control is still unknown. Does
ERb directly modulate the chromatin state
of promoters or enhancers of immune
genes? Or does it indirectly influence
basal transcription by interfering with the
assembly of corepressors or coactivator
complexes. Another intriguing possibility
is that ERb modulates the expression of
noncoding RNAs, in particular large inter-
genic noncoding RNAs, and that these
may in return account for the effect of
ERb on the expression of immune genes.
Together the results reported by Saijo
and colleagues underline the complexity
of the ERb biology during an inflammatory
response and suggest that its effects are
context dependent. Thus, the net outcome
of ERb may rest upon an equilibrium
that depends on the bioavailability of its
endogenous ligands. Indeed, Saijo and
colleagues find that the ligand 17b-estra-
diol (17b-E2) can antagonize the anti-
inflammatory activities of ADIOL, and
microglia’s innate immune reaction to
LPS increases in the presence of 17b-E2
in vivo (Soucy et al., 2005). Although this
makes the net outcome of ERb activity on
gene transcription hard to predict in vivo,
it suggests a fascinating mechanism to
explainwhy relapsing-remittingMSaffects
females more than males. In females, the
competition among the steroid ligands for
ERb in an inflammatory context may be
shifted to promote inflammation in the
CNS (Figure 1). Moreover, anovulants
(i.e., birth control medicine) and environ-
mental factors, such as estrogen analogs
derived from plants, may also shift the
equilibriumofERb ligands towardapheno-
type that promotes relapsing-remitting
MS. These hypotheses clearly warrant
further investigations to link mechanisti-
cally environmental factors, sex steroids,
DHEA metabolism in microglia, neuroin-
flammation, and chronic diseases.
The study by Saijo and colleagues
brings us one step closer to better under-
standing the critical role that microglia
play in sensing the cerebral environment
and the resulting consequences of their
inflammatory response modulated by
nuclear receptors in a gender-specific
manner. Compared to the robust anti-
inflammatory properties of glucocorticoid
receptors, ERb has not been considered
a major modulator of the innate immune
response. This elegant series of experi-
ments by Saijo and colleagueswill change
this view and hopefully accelerate our
understanding of the roles of ERb in MS
and, possibly, in autoimmune diseases
more generally, including how gender
affects their development.
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Hormonal regulation of glucose and lipid metabolism is pivotal for metabolic homeostasis and
energy balance. Two studies in this issue ofCell (Mihaylova et al., 2011 andWang et al., 2011) intro-
duce a new conserved signaling mechanism controlling catabolic gene expression: class IIa
histone deacetylases (HDACs) regulate Foxo activity in Drosophila and mice.The hormones insulin and glucagon
are central to regulating glucose homeo-
stasis in vertebrates (Biddinger and Kahn,
2006). During states of fasting, glucagon
initiates the production of glucose (i.e.,
gluconeogenesis) in the liver by increasing
the transcription of gluconeogenic en-
zymes, such as glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate car-
boxykinase (PEPCK). When nutrients are
increased, insulin then attenuates gluco-
neogenesis in the liver and initiates
glucoseuptake inperipheral tissues, stabi-
lizing blood glucose concentrations while
also promoting anabolic processes and
energy storage. When this regulation of
glucose homeostasis dysfunctions, meta-
bolic disorders develop, such as type 2
diabetes and metabolic syndrome. Thus,
deciphering the details of this signaling
network promises to provide new strate-
gies for treating these diseases. Now two
studies in this issue of Cell take the firststep toward bringing this promise to
fruition; they uncover a pivotal role for
histone deacetylases in glucose homeo-
stasis, suggesting that established HDAC
inhibitors may be effective at mitigating
diabetes and metabolic syndrome.
In the liver, glucagon stimulates tran-
scription of gluconeogenic genes through
a signaling pathway (Figure 1, left) that
includes the cAMP-dependent Protein
Kinase A (PKA) and the AMP-dependent
protein kinase family members AMPK
(AMP-activated protein kinase), SIK1
(salt-inducible kinase 1), and SIK2 (Viollet
et al., 2009). AMPK and its upstream
kinase LKB1 (Liver Kinase 1) inhibit gluco-
neogenic gene transcription in hepatic
cells by suppressing nuclear transloca-
tion of the transcriptional coactivator
CRTC2 (CREB-regulated transcription
coactivator 2)/TORC2. Once PKA blocks
AMPK and SIK1/2, CRTC2 associates
with the transcription factor CREB toinduce the coactivator PGC-1a (peroxi-
some proliferator-activated receptor
gamma coactivator-1 alpha), which in
turn associates with the transcription
factors Foxo1 (Forkhead box o1) and
HNF4a (hepatocyte nuclear factor 4
alpha) to activate gluconeogenic gene
expression (Altarejos and Montminy,
2011; Viollet et al., 2009).
Insulin attenuates glucose production
by influencing the samepathway (Figure1,
left). Activation of the insulin-responsive
Akt kinase results in the inhibition of
CRTC2 via SIK1/2, as well as phosphory-
lation and inactivation of Foxo (Viollet
et al., 2009).
In addition to this hormone-mediated
control of glucose metabolism, the cell’s
energy balance also influences glucose
production through a family of class III
histone deacetylases (HDACs), called
Sirtuins, which couple deacetylation with
NAD (nicotinamide adenine dinucleotide)145, May 13, 2011 ª2011 Elsevier Inc. 497
